Find us on:

Dutch researchers in breakthrough study:

Low Dose Naltrexone (LDN) helps 3 out of 4 patients with Inflammatory Bowel Disease (IBD) who are resistant to other treatments.

Resistance to all approved drugs poses a major problem for IBD patients. One out of three patients simply do not respond to any drug therapy, and very often this leads to life-altering surgery.

Such patients, described as “treatment-refractory” now have hope with LDN, a simple, safe, and low-cost pill taken once a day. Dutch researchers at the prestigious Erasmus University Medical Center in Rotterdam have found that LDN helps 3 out of 4 treatment-refractory patients, and 1 out of 4 achieves clinical remission.

LDN helps 3 out of 4 treatment-refractory patients, and 1 out of 4 achieves clinical remission

In a study conducted on 47 IBD patients, the researchers added a once-daily LDN pill to the ineffective treatment regimen, and closely studied their response over a 3 month period. By the end of 12 weeks, 74.5% showed clinical improvement and 25.5% achieved remission.

Looking at the intestinal cells of these patients under a microscope, the researchers found significant improvement in wound healing, confirming that the effect was objective and scientifically explainable.

Moshe Rogosnitzky, founder of LDNscience and initiator of the first clinical trial for Crohn’s disease at Penn State University in 2002, commented: “It is very gratifying that 11 years after we published our first positive study of LDN’s benefit in Crohn’s disease, there is further confirmation of its benefit in a significant subset of patients for whom the only remaining hope was surgery. This emphasizes the need to advance development of LDN through large studies and have it officially approved as an IBD therapy. Such approval will enable LDN to be used as an early safe therapy, thereby saving many patients from surgery and helping to restore their health”.

Read the published study here